Trial Information

Summary: A Randomized Clinical Trial of Bupropion and Paroxetine for the Treatment of High-Risk Major Depressive Disorder.

The Department of Neuroscience at the New York State Psychiatric Institute is conducting a research study on the prevention of suicidal behavior in Major Depressive Disorder using medications, and is looking for people interested in participating. The goal of our study is to compare the effect of Wellbutrin (bupropion) versus Paxil (paroxetine) on the vulnerability to suicidal behavior during a 6-month period following a Major Depressive Episode. Both Wellbutrin and Paxil are antidepressants which have been approved by the Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder.

We are offering free outpatient medication monitoring visits at the Neuroscience Clinic for a period of 6 months.

If you are interested, or have a family member who is suffering from Major Depressive Disorder, and would like further information, please call Sadia Chaudhury at 212-543-5834.

Inclusion Criteria

• Between 18 and 75 years old
• Currently in a Major Depressive Episode
• History of a past suicide attempt
• Must live within the New York City metro area, since patients are required to come in regularly for psychopharmacological treatment visits

Exclusion Criteria:

• History of Bipolar Disorder
• Responded poorly to Paxil or Wellbutrin in the past

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.